Comments
Jubilant Life Sciences Ltd has reported a loss of Rs 64 crore in fourth quarter of 2011-12. The loss is because of payout on exceptional items, impairment of assets of assets and depreciation in the value of Indian rupee. Without these expenses, the pharma firm would have reported normalised profit after tax of Rs 83 crore.
Jubilant's income rose 31 per cent to Rs 1,176 crore during January-March 2012 against the same period previous year. At present, the company has $ 443 million of foreign loans and Rs 1,560 crore of domestic borrowings.
Jubilant stock closed 0.53 per cent down at Rs 178.20 on the BSE on Monday.
The company said it targets to achieve compounded annual growth of more than 20 per cent for the next three years.
The growth would be on account of higher utilisation of new, expanded and existing capacities in life science ingredients and contract manufacturing business. At the same time, new product launches and expansion in new territories in APIs, generics and specialty pharma businesses would fuel growth, it added.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.